Tags

Type your tag names separated by a space and hit enter

Cannabis in cancer care.
Clin Pharmacol Ther 2015; 97(6):575-86CP

Abstract

Cannabis has been used in medicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa, mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, the main bioactive cannabinoid in the plant, has been available as a prescription medication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoids may be of benefit in the treatment of cancer-related pain, possibly synergistic with opioid analgesics. Cannabinoids have been shown to be of benefit in the treatment of HIV-related peripheral neuropathy, suggesting that they may be worthy of study in patients with other neuropathic symptoms. Cannabinoids have a favorable drug safety profile, but their medical use is predominantly limited by their psychoactive effects and their limited bioavailability.

Authors+Show Affiliations

Hematology-Oncology, San Francisco General Hospital, Department of Medicine, University of California San Francisco, San Francisco, California, USA.Biochemistry and Molecular Biology, School of Biology, Complutense University, and Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25777363

Citation

Abrams, D I., and M Guzman. "Cannabis in Cancer Care." Clinical Pharmacology and Therapeutics, vol. 97, no. 6, 2015, pp. 575-86.
Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther. 2015;97(6):575-86.
Abrams, D. I., & Guzman, M. (2015). Cannabis in cancer care. Clinical Pharmacology and Therapeutics, 97(6), pp. 575-86. doi:10.1002/cpt.108.
Abrams DI, Guzman M. Cannabis in Cancer Care. Clin Pharmacol Ther. 2015;97(6):575-86. PubMed PMID: 25777363.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabis in cancer care. AU - Abrams,D I, AU - Guzman,M, Y1 - 2015/04/17/ PY - 2015/01/05/received PY - 2015/03/09/accepted PY - 2015/3/18/entrez PY - 2015/3/18/pubmed PY - 2015/8/13/medline SP - 575 EP - 86 JF - Clinical pharmacology and therapeutics JO - Clin. Pharmacol. Ther. VL - 97 IS - 6 N2 - Cannabis has been used in medicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa, mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, the main bioactive cannabinoid in the plant, has been available as a prescription medication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoids may be of benefit in the treatment of cancer-related pain, possibly synergistic with opioid analgesics. Cannabinoids have been shown to be of benefit in the treatment of HIV-related peripheral neuropathy, suggesting that they may be worthy of study in patients with other neuropathic symptoms. Cannabinoids have a favorable drug safety profile, but their medical use is predominantly limited by their psychoactive effects and their limited bioavailability. SN - 1532-6535 UR - https://www.unboundmedicine.com/medline/citation/25777363/Cannabis_in_cancer_care_ L2 - https://doi.org/10.1002/cpt.108 DB - PRIME DP - Unbound Medicine ER -